Baird Rates Taysha Gene Therapies (TSHA) buy, $15 Price Target
Baird maintains its buy rating on Taysha Gene Therapies with a $15 target, a 120.26% upside from the current price.
Reviewed by automated data checks against the source data. How we make and check alerts
Baird rated Taysha Gene Therapies, Inc. ($TSHA) "buy" with a $15 price target on June 30, 2026.
Since the rating, $TSHA is down 4.5% after 1 week, down 13.7% after 1 month and down 46.8% to date (from the $6.81 close on Jun 30, 2026).
TSHA
Taysha Gene Therapies, Inc.
Key Points
- Baird reiterated its buy rating on Taysha Gene Therapies, Inc. (TSHA) with a price target of $15 on June 30, 2026.
- Baird's $15 price target implies 120.26% upside from Taysha Gene Therapies, Inc.'s ($TSHA) current $6.81 share price.
- Shares of TSHA traded at $6.73 on Tuesday, with a market cap of $1.82 billion and a 52-week range of $2.25 to $7.30.
- Multiple insiders, including John III Stalfort and Laura Sepp-Lorenzo, made significant stock purchases on June 1, 2026.
Get $TSHA trade alerts by text
We text you when insiders, Congress or big funds trade $TSHA. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Taysha Gene Therapies, Inc. alert may contain errors. Disclosures
On June 30, 2026, Baird reiterated its buy rating for Taysha Gene Therapies, Inc. (TSHA) with a price target of $15. This analyst action reflects continued confidence in the company's potential.
Baird vs. the S&P 500
Hypothetical returns from Baird's disclosed trades, not real profit or advice. How we model this.
Other Institutional Activity in Taysha Gene Therapies
RA Capital Management maintained its position in Taysha Gene Therapies with 23,555,648 shares valued at about $105.3 million. Meanwhile, Goldman Sachs Group added 8,676,906 shares, increasing its holdings by 63.4% to 22,369,645 shares worth roughly $99.99 million. Avoro Capital Advisors held steady with 21,700,000 shares valued at $96.99 million. BlackRock trimmed its holdings by 277,521 shares, resulting in an ownership of 18,365,608 shares valued at about $82.09 million. Vestal Point Capital increased its position by 4,250,000 shares, a 30.9% boost, bringing its total to 18,000,000 shares worth $80.46 million.
Taysha Gene Therapies, Inc. Stock Up 35.7%
Shares of NasdaqGS:TSHA traded near $6.73 on Tuesday. Taysha Gene Therapies has a market cap of approximately $1.82 billion. The stock has a 52-week low of $2.25 and a 52-week high of $7.30, with a 50-day moving average of $6.13 and a 200-day moving average of $4.97. The company’s current ratio is 14.04, and its quick ratio is 13.76, indicating strong liquidity. The debt-to-equity ratio stands at 32.34.
$TSHA price target
Taysha Gene Therapies, Inc. daily closes and this analyst's $15 target. Not advice.
Recent Earnings
Taysha Gene Therapies reported revenue of $7.47 million. However, the company is not yet profitable, with a negative return on equity of -97.28% and a net margin of 0.0%. The next earnings report is expected on August 12, 2026.
Insider Buying and Selling at Taysha Gene Therapies, Inc.
On June 1, 2026, several insiders made stock purchases. John III Stalfort acquired 42,671 shares, Alison Long purchased 42,671 shares, and Laura Sepp-Lorenzo bought 42,671 shares. Additionally, Sepp-Lorenzo and Stalfort each purchased an additional 21,335 shares, while Phillip Donenberg also acquired 21,335 shares. These transactions were not part of a pre-planned trading program.
Analysts Set New Price Targets
On June 30, 2026, Baird maintained its buy rating for Taysha Gene Therapies with a price target of $15. Other firms like BMO Capital and B of A Securities also reiterated buy ratings, with targets of $14 and $10, respectively. The consensus among analysts remains strong buy, with an average target price of $12.85 from 13 analysts.
About Taysha Gene Therapies
Taysha Gene Therapies, Inc. is a biotechnology company based in Dallas, Texas, focusing on developing gene therapies for severe monogenic diseases of the central nervous system. The company works on various therapies, including treatments for giant axonal neuropathy and Rett syndrome. Led by CEO Sean P. Nolan, Taysha collaborates with The University of Texas Southwestern Medical Center to advance its research and development.
Bottom Line
Investors are keeping a close eye on Taysha Gene Therapies as Baird reiterates its buy rating with a $15 target. The company's financial health and promising pipeline in gene therapies make it a significant player in the biotechnology sector. As with all 13F filings and analyst ratings, these insights reflect past actions and opinions, not current or future performance predictions.
Related Filing Alerts
Source: Baird's rating change on $TSHA (Jun 30, 2026). Written by software, not financial advice. How we make alerts